Literature DB >> 12460237

Recurrent palmar-plantar erythrodysaesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemia.

Julie H Crawford1, John W Eikelboom, Andrew McQuillan.   

Abstract

Palmar-plantar erythrodysaesthesia (PPE) is an uncommon cutaneous complication of cytotoxic chemotherapy which generally presents as a painful erythema involving the palms and soles. It has been suggested that PPE caused by cytarabine does not recur with subsequent cytarabine re-challenge. We report a patient with recurrent, increasingly severe episodes of PPE, ultimately complicated by a severe bullous eruption, following successive cycles of high-dose cytarabine for the treatment of acute lymphoblastic leukaemia. Contrary to previous recommendations, our experience cautions against the further use of high-dose cytarabine in patients who develop PPE, and is a timely reminder of the potential toxicity of this agent, which is now increasingly being used as first-line treatment in the management of haematologic malignancies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12460237     DOI: 10.1034/j.1600-0609.2002.02834.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  4 in total

1.  [Hand-foot syndrome with capecitabine therapy].

Authors:  A Marini; U R Hengge
Journal:  Hautarzt       Date:  2007-06       Impact factor: 0.751

2.  Cytarabine and Doxorubicin-Induced Palmoplantar Erythrodysesthesia Syndrome: The Possible Role of Voriconazole Interaction.

Authors:  Maria Tavakoli-Ardakani; Shirin Haghighi; Shervin Shokouhi; Bahareh Abtahi-Naeini; Mohsen Meidani; Rezvan Hassanpour; Ali Saffaei
Journal:  Eurasian J Med       Date:  2019-10

Review 3.  Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.

Authors:  Brian A Baldo; Nghia H Pham
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

4.  Hand-foot syndrome with docetaxel: a five-case series.

Authors:  Mirna H Farhat; Nagi S El-Saghir; Ali I Shamseddine
Journal:  Ann Saudi Med       Date:  2008 Sep-Oct       Impact factor: 1.526

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.